Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
نویسندگان
چکیده
منابع مشابه
Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
I n the article Gaziano et al, “Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects,” which published online October 12, 2012, and appeared in the October 2012 issue of the journal ( J Am Heart Assoc. 2012;1:e002279 doi: 10.1161/JAHA.112.002279), an error occurred in Table 3. In the row “CV death”,...
متن کاملEffect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
BACKGROUND Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration-approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative risk among bromocriptine-QR-treated subjects in a prespecified composite cardiovascular (CV) end poi...
متن کاملEffect of Bromocriptine Mesylate as Add-On Therapy in Obese Type 2 Diabetes Mellitus Patients
Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese typ...
متن کاملeffect of bromocriptine mesylate as add-on therapy in obese type 2 diabetes mellitus patients
six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (hba1c), fasting blood sugar, postprandial blood sugar, and weight of 22 indian obese patients with type 2 diabetes mellitus with no serious adverse events. therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese typ...
متن کاملEffect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
CONTEXT Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of PPARs (alpha and gamma) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory committee on September 9, 2005, resulting in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Heart Association
سال: 2012
ISSN: 2047-9980,2047-9980
DOI: 10.1161/jaha.112.002279